Beyond Air (XAIR) to Release Earnings on Friday

Beyond Air (NASDAQ:XAIR) is expected to issue its Q3 2026 results before the market opens on Friday, February 13th. Analysts expect Beyond Air to post earnings of ($0.54) per share and revenue of $2.1460 million for the quarter. Investors can check the company’s upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Friday, February 13, 2026 at 8:00 AM ET.

Beyond Air (NASDAQ:XAIR) last announced its earnings results on Monday, November 10th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.15). Beyond Air had a negative return on equity of 261.08% and a negative net margin of 632.51%.The company had revenue of $1.82 million during the quarter, compared to analysts’ expectations of $2.54 million. On average, analysts expect Beyond Air to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Beyond Air Trading Down 4.1%

NASDAQ XAIR opened at $1.05 on Friday. The stock’s 50-day simple moving average is $1.15 and its two-hundred day simple moving average is $1.91. Beyond Air has a twelve month low of $0.67 and a twelve month high of $10.40. The company has a quick ratio of 3.73, a current ratio of 4.24 and a debt-to-equity ratio of 0.77. The company has a market capitalization of $8.37 million, a price-to-earnings ratio of -0.14 and a beta of 0.39.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Weiss Ratings reiterated a “sell (e)” rating on shares of Beyond Air in a research report on Monday, December 22nd. Rodman & Renshaw began coverage on Beyond Air in a research note on Tuesday, January 20th. They issued a “buy” rating for the company. Finally, D. Boral Capital reissued a “buy” rating and set a $11.00 price target on shares of Beyond Air in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $11.00.

Institutional Trading of Beyond Air

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Alyeska Investment Group L.P. bought a new position in shares of Beyond Air in the third quarter worth approximately $1,753,000. Geode Capital Management LLC grew its stake in shares of Beyond Air by 1.5% in the second quarter. Geode Capital Management LLC now owns 838,319 shares of the company’s stock worth $144,000 after purchasing an additional 12,598 shares during the last quarter. Virtu Financial LLC purchased a new position in Beyond Air during the 3rd quarter valued at about $48,000. Finally, Osaic Holdings Inc. raised its position in Beyond Air by 26.4% during the 2nd quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock valued at $29,000 after purchasing an additional 34,000 shares during the last quarter. Institutional investors own 31.50% of the company’s stock.

Beyond Air Company Profile

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.